DURHAM, N.C. and HYDERABAD, India, May 27 /PRNewswire/ -- Cato Research Ltd. ("Cato Research"), a global contract research and development organization ("CRO"), and Neuland Laboratories Ltd. (Neuland), a high-quality contract manufacturer of bulk active pharmaceutical ingredients, announced today a new joint venture which will establish a CRO located in Hyderabad, India. Cato Research Neuland India, Ltd., the new joint venture company formed by Cato Research, Cato Research Israel Ltd., and Neuland will assist health care companies in efficiently bringing innovative drugs to market while using high quality and cost effective resources located in India.
Cato Research will provide business development, personnel training, senior management recruitment and implementation of SOP guidelines. In collaboration with Cato BioVentures, the venture capital affiliate of Cato Research, Cato Research will also provide CRO services to include clinical studies, data management activities, statistical analysis, as well as regulatory services.
"This joint venture further allows Cato to expand its international presence and better serve our sponsors," said Dr. Allen Cato, M.D., Ph.D., Chief Executive Officer of Cato Research and Principal of Cato BioVentures. "The addition of India into Cato Research's international network increases our ability to conduct multinational clinical trials and provide a wide range of CRO services in the international arena."
"We are pleased to be working with Cato Research and Cato BioVentures to accelerate development and commercialization of several new innovative products," said Dr. D. R. Rao, Chairman and Managing Director for Neuland Laboratories. "Our strategic interests are well-aligned, as each party offers unique strengths to make this arrangement successful. This joint venture takes Neuland one step closer towards our objective of becoming an end-to-end service provider for the Pharmaceutical Industry."
|SOURCE Cato Research Ltd.|
Copyright©2008 PR Newswire.
All rights reserved